TY - JOUR
T1 - Pembrolizumab-induced Stevens–Johnson Syndrome with Severe Ocular Complications
AU - Ryu, Soyoung
AU - Jun, Ikhyun
AU - Kim, Tae Im
AU - Seo, Kyoung Yul
AU - Kim, Eung Kweon
N1 - Publisher Copyright:
© 2021 Taylor & Francis Group, LLC.
PY - 2022
Y1 - 2022
N2 - Purpose: To report a unique case of Stevens–Johnson syndrome (SJS) with severe ocular complications induced by pembrolizumab, an immune checkpoint inhibitor. Case presentation: A 64-year-old man with urothelial cancer presented with bilateral corneal epithelial defect and conjunctival pseudo-membrane formation with erythematous patches on the four extremities, abdomen, and back. He had urothelial cancer with multifocal lesions in the renal pelvis and left ureter, and para-aortic metastatic lymph nodes. Accordingly, pembrolizumab treatment was planned. Generalized skin eruption occurred 4 days after the first cycle of pembrolizumab treatment, and ocular symptoms occurred 2 weeks after the first cycle. The patient’s symptoms improved after cessation of pembrolizumab treatment and administration of steroids systemically. Conclusions: Immune checkpoint inhibitors, including pembrolizumab, have been developed recently and are widely used in the treatment of various cancers. However, it should be noted that the drugs may cause adverse events such as SJS with severe ocular complications.
AB - Purpose: To report a unique case of Stevens–Johnson syndrome (SJS) with severe ocular complications induced by pembrolizumab, an immune checkpoint inhibitor. Case presentation: A 64-year-old man with urothelial cancer presented with bilateral corneal epithelial defect and conjunctival pseudo-membrane formation with erythematous patches on the four extremities, abdomen, and back. He had urothelial cancer with multifocal lesions in the renal pelvis and left ureter, and para-aortic metastatic lymph nodes. Accordingly, pembrolizumab treatment was planned. Generalized skin eruption occurred 4 days after the first cycle of pembrolizumab treatment, and ocular symptoms occurred 2 weeks after the first cycle. The patient’s symptoms improved after cessation of pembrolizumab treatment and administration of steroids systemically. Conclusions: Immune checkpoint inhibitors, including pembrolizumab, have been developed recently and are widely used in the treatment of various cancers. However, it should be noted that the drugs may cause adverse events such as SJS with severe ocular complications.
KW - Pembrolizumab
KW - Stevens–Johnson syndrome
KW - immune checkpoint inhibitors
KW - ocular manifestation
KW - severe ocular complications
UR - http://www.scopus.com/inward/record.url?scp=85103988988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103988988&partnerID=8YFLogxK
U2 - 10.1080/09273948.2021.1896006
DO - 10.1080/09273948.2021.1896006
M3 - Article
C2 - 33826467
AN - SCOPUS:85103988988
SN - 0927-3948
VL - 30
SP - 1533
EP - 1535
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
IS - 6
ER -